Search Results - "Johnston, P. B."

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma by Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M

“…The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL)…”
Get full text

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma by Wilcox, R A, Ristow, K, Habermann, T M, Inwards, D J, Micallef, I N M, Johnston, P B, Colgan, J P, Nowakowski, G S, Ansell, S M, Witzig, T E, Markovic, S N, Porrata, L

“…Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models,…”
Get full text

Bowel perforation in intestinal lymphoma: incidence and clinical features by Vaidya, R., Habermann, T.M., Donohue, J.H., Ristow, K.M., Maurer, M.J., Macon, W.R., Colgan, J.P., Inwards, D.J., Ansell, S.M., Porrata, L.F., Micallef, I.N., Johnston, P.B., Markovic, S.N., Thompson, C.A., Nowakowski, G.S., Witzig, T.E.

“…Perforation is a serious life-threatening complication of lymphomas involving the gastrointestinal (GI) tract. Although some perforations occur as the initial…”
Get full text

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study by Nowakowski, G S, LaPlant, B, Habermann, T M, Rivera, C E, Macon, W R, Inwards, D J, Micallef, I N, Johnston, P B, Porrata, L F, Ansell, S M, Klebig, R R, Reeder, C B, Witzig, T E

“…Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish…”
Get full text

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center by Dispenzieri, A, Seenithamby, K, Lacy, M Q, Kumar, S K, Buadi, F K, Hayman, S R, Dingli, D, Litzow, M R, Gastineau, D A, Inwards, D J, Micallef, I N, Ansell, S M, Johnston, P B, Porrata, L F, Patnaik, M M, Hogan, W J, Gertz, M A A

“…The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of ‘tumor burden’ but…”
Get full text

Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics by Ungerechts, G, Frenzke, M E, Yaiw, K-C, Miest, T, Johnston, P B, Cattaneo, R

“…Measles virus (MV)-PNP H blind antiCD20 is a CD20-targeted and prodrug convertase-armed MV that temporarily controls growth of lymphoma xenografts in severe…”
Get full text

CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy by Yaiw, K-C, Miest, T S, Frenzke, M, Timm, M, Johnston, P B, Cattaneo, R

“…New therapeutic modalities for B-cell non-Hodgkin's lymphomas (B-NHL) are needed, especially for relapsing and aggressive subtypes. Toward this end, we…”
Get full text

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma by JOAO, C, PORRATA, L. F, INWARDS, D. J, ANSELL, S. M, MICALLEF, I. N, JOHNSTON, P. B, GASTINEAU, D. A, MARKOVIC, S. N

“…Autologous stem cell transplantation (ASCT) is an effective treatment strategy for mantle-cell lymphoma (MCL) demonstrating significantly prolonged…”
Get full text

Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients by Zirakzadeh, A, Gastineau, D A, Mandrekar, J N, Burke, J P, Johnston, P B, Patel, R

“…There are no cohort studies describing outcomes of patients colonized with vancomycin-resistant enterococci (VRE) undergoing allogeneic hematopoietic stem cell…”
Get full text

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma by Porrata, L F, Rsitow, K, Inwards, D J, Ansell, S M, Micallef, I N, Johnston, P B, Habermann, T M, Witzig, T E, Colgan, J P, Nowakowski, G S, Thompson, C A, Markovic, S N

“…A specific predictor during routine follow-up to ascertain risk for relapse after standard chemotherapy in non-Hodgkin's lymphoma (NHL) has not been…”
Get full text

Intraocular use of rituximab by KITZMANN, A. S, PULIDO, J. S, DIXON, L. E, SALOMAO, D. R, CAMERON, J. D, MOHNEY, B. G, BARATZ, K. H, GRUBE, T, MARLER, R. J, DONALDSON, M. J, O'NEILL, B. P, JOHNSTON, P. B, JOHNSON, K. M

“…To evaluate the toxicity of 1 mg of intraocular rituximab and to present a small case-series of patients treated with intravitreal rituximab. Rituximab (1…”
Get full text

CD34 cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies by Holtan, S G, Hogan, W J, Elliott, M A, Ansell, S M, Inwards, D J, Porrata, L F, Johnston, P B, Micallef, I N, Lacy, M Q, Gastineau, D A, Litzow, M R

“…The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic…”
Get full text

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation by Costa, L J, Micallef, I N, Inwards, D J, Johnston, P B, Porrata, L F, Ansell, S M

“…We explored the concomitant effect of the International Prognostic Index at the time of relapse (IPI-R) and the time from initial diagnosis to relapse (TTR) on…”
Get full text

Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma by Johnston, P B, Wiseman, G A, Micallef, I N M

“…Positron emission tomography (PET) utilizing fluorodeoxyglucose (FDG) has an ever-increasing role in the management of numerous malignancies. FDG PET in…”
Get full text

Delayed hypersensitivity to hyaluronidase (Hyalase™) used during cataract surgery by Feighery, C., McCoy, E. P., Johnston, P. B., Armstrong, D. K. B.

Get full text

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma by PORRATA, Luis F, RISTOW, Kay, THOMPSON, Carrie, MARKOVIC, Svetomir N, COLGAN, Joseph P, HABERMANN, Thomas M, WITZIG, Thomas E, INWARDS, David J, ANSELL, Stephen M, MICALLEF, Ivana N, JOHNSTON, Patrick B, NOWAKOWSKI, Grzegorz S

“…Lymphopenia and tumor-associated macrophages are negative prognostic factors for survival in classical Hodgkin's lymphoma. We, therefore, studied whether the…”
Get full text

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization by Naina, H V, Pruthi, R K, Inwards, D J, Dingli, D, Litzow, M R, Ansell, S M, William, H J, Dispenzieri, A, Buadi, F K, Elliott, M A, Gastineau, D A, Gertz, M A, Hayman, S R, Johnston, P B, Lacy, M Q, Micallef, I N, Porrata, L F, Kumar, S

“…The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying…”
Get full text

Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation by Kansagra, A, Inwards, D J, Ansell, S M, Micallef, I N, Johnston, P B, Hogan, W J, Markovic, S N, Porrata, L F

“…The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS…”
Get full text

Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation by Kansagra, A, Inwards, D J, Ansell, S M, Micallef, I N, Johnston, P B, Hogan, W J, Markovic, S N, Porrata, L F

“…The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS…”
Get full text

INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078E by Desai, S., Laplant, B., Macon, W., Young, J., King, R., Wang, Y., Inwards, D., Micallef, I., Johnston, P. B., Porrata, L. F., Ansell, S. M., Habermann, T. M., Witzig, T. E., Nowakowski, G. S.

Get full text